Erschienen in:
01.06.2011 | Letter to the Editor
Circulating Fibroblast Growth Factor 23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation
verfasst von:
James Mahon, Miriam Casey
Erschienen in:
Calcified Tissue International
|
Ausgabe 6/2011
Einloggen, um Zugang zu erhalten
Excerpt
We read with interest in your November issue the article “Circulating Fibroblast Growth Factor 23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation” by Sridharan et al. While we welcome their input into elucidating the use of FGF-23 as a biomarker in osteoporosis treatment, we would like to address a few issues: the unusual baseline characteristics of the cohort studied and the small number of patients in the study. …